Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:CRSP NASDAQ:NTLA On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$54.83+4.6%$52.34$34.87▼$78.48$5.29B1.741.89 million shs1.73 million shsNTLAIntellia Therapeutics$14.09+2.8%$13.65$6.83▼$28.25$1.70B1.937.52 million shs5.78 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+4.60%+6.20%+6.01%+12.49%+60.01%NTLAIntellia Therapeutics+2.77%+6.26%+1.88%+14.74%+93.28%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCRSPCRISPR Therapeutics$54.83+4.6%$52.34$34.87▼$78.48$5.29B1.741.89 million shs1.73 million shsNTLAIntellia Therapeutics$14.09+2.8%$13.65$6.83▼$28.25$1.70B1.937.52 million shs5.78 million shsElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCRSPCRISPR Therapeutics+4.60%+6.20%+6.01%+12.49%+60.01%NTLAIntellia Therapeutics+2.77%+6.26%+1.88%+14.74%+93.28%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCRSPCRISPR Therapeutics 2.56Moderate Buy$65.9420.26% UpsideNTLAIntellia Therapeutics 2.35Hold$20.5545.82% UpsideCurrent Analyst Ratings BreakdownLatest NTLA and CRSP Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/6/2026CRSPCRISPR Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$80.00 ➝ $82.004/28/2026NTLAIntellia Therapeutics The Goldman Sachs GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetSell$8.00 ➝ $9.004/28/2026NTLAIntellia Therapeutics CitigroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingOutperform4/28/2026NTLAIntellia Therapeutics Canaccord Genuity GroupSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$48.00 ➝ $58.004/28/2026NTLAIntellia Therapeutics Citizens JmpSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetMarket Outperform$28.00 ➝ $30.004/27/2026NTLAIntellia Therapeutics Leerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingSet Price Target$35.004/27/2026NTLAIntellia Therapeutics Morgan StanleySubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetEqual Weight$11.00 ➝ $15.004/27/2026NTLAIntellia Therapeutics Robert W. BairdSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetNeutral$7.00 ➝ $13.004/27/2026NTLAIntellia Therapeutics Chardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$27.00 ➝ $30.004/21/2026NTLAIntellia Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)4/20/2026CRSPCRISPR Therapeutics Weiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 5/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCRSPCRISPR Therapeutics$3.51M1,506.65N/AN/A$18.81 per share2.91NTLAIntellia Therapeutics$67.67M25.08N/AN/A$5.80 per share2.43Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCRSPCRISPR Therapeutics-$581.60M-$6.22N/AN/AN/A-13,856.54%-25.66%-20.39%5/11/2026 (Estimated)NTLAIntellia Therapeutics-$412.69M-$3.83N/AN/AN/A-609.85%-56.81%-45.34%5/14/2026 (Estimated)Latest NTLA and CRSP EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/14/2026Q1 2026NTLAIntellia Therapeutics-$0.92N/AN/AN/A$13.81 millionN/A5/4/2026Q1 2026CRSPCRISPR Therapeutics-$1.2185-$1.28-$0.0615-$1.28$6.06 million$1.46 million3/31/2026Q1 2026CRSPCRISPR TherapeuticsN/A-$1.28N/A-$1.28N/A$1.46 million2/26/2026Q4 2025NTLAIntellia Therapeutics-$0.99-$0.83+$0.16-$0.83$12.17 million$23.02 million2/13/2026Q4 2025CRSPCRISPR Therapeutics-$1.15-$1.37-$0.22-$1.37$4.72 million$0.86 millionCompare DividendsCompanyAnnual PayoutDividend Yield5-Year Annualized Dividend GrowthPayout RatioYears of Consecutive GrowthCRSPCRISPR TherapeuticsN/AN/AN/AN/AN/ANTLAIntellia TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCRSPCRISPR Therapeutics0.3217.9713.32NTLAIntellia TherapeuticsN/A5.085.08Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCRSPCRISPR Therapeutics69.20%NTLAIntellia Therapeutics88.77%Insider OwnershipCompanyInsider OwnershipCRSPCRISPR Therapeutics4.30%NTLAIntellia Therapeutics3.10%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCRSPCRISPR Therapeutics46096.45 million92.30 millionOptionableNTLAIntellia Therapeutics600120.46 million116.73 millionOptionableNTLA and CRSP HeadlinesRecent News About These CompaniesCanal Insurance CO Invests $899,000 in Intellia Therapeutics, Inc. $NTLAMay 8 at 3:40 AM | marketbeat.comAssessing Intellia Therapeutics (NTLA) Valuation After Positive Phase 3 HAELO Results And BLA Submission For Lonvo ZMay 7 at 11:49 PM | finance.yahoo.comIntellia Therapeutics, Inc. (NTLA) Expected to Beat Earnings Estimates: Can the Stock Move Higher?May 7 at 11:01 AM | zacks.comIntellia Therapeutics (NTLA) Projected to Post Earnings on ThursdayMay 7 at 3:48 AM | marketbeat.comIntellia Therapeutics to Participate in Upcoming Investor ConferencesMay 5, 2026 | globenewswire.comNTLA Q2 EPS Increased by Brookline Capital MarketsMay 4, 2026 | marketbeat.comIntellia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 1, 2026 | globenewswire.comIntellia Therapeutics (NTLA) Is Down 15.1% After Phase 3 lonvo-z Data And $180M Equity Raise - Has The Bull Case Changed?April 30, 2026 | finance.yahoo.comIntellia Therapeutics stock tumbles on dilutive offeringApril 30, 2026 | au.investing.comIntellia Therapeutics prices $180M stock offering at discountApril 30, 2026 | msn.comWhy Intellia Therapeutics, Inc.’s (NTLA) Stock Is Down 6.01%April 30, 2026 | aaii.comAIntellia Therapeutics (NASDAQ:NTLA) Shares Gap Down - What's Next?April 29, 2026 | marketbeat.comIntellia Therapeutics Announces Pricing of Public Offering of Common StockApril 29, 2026 | globenewswire.comCathie Wood just made a massive bet on these two top AI stocksApril 29, 2026 | finbold.comFIntellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $58.00 at Canaccord Genuity GroupApril 28, 2026 | marketbeat.comNTLA Falls 4% Despite Strong Phase III HAE Data, Initiates Rolling BLAApril 28, 2026 | zacks.comIntellia Therapeutics (NASDAQ:NTLA) Stock Price Up 6% After Analyst UpgradeApril 28, 2026 | marketbeat.comIntellia Therapeutics (NASDAQ:NTLA) Price Target Raised to $30.00 at Citizens JmpApril 28, 2026 | marketbeat.comIntellia Therapeutics And Wall Street Continue To Play Their D&D Game - Data And DoubtApril 28, 2026 | seekingalpha.comIntellia Therapeutics Posts Phase 3 HAELO Win for lonvo-z, Begins Rolling FDA BLA FilingApril 27, 2026 | marketbeat.comIntellia Therapeutics, Inc. (NTLA) Discusses Topline Phase 3 HAELO Trial Results for Lonvoguran Ziclumeran in Hereditary Angioedema TranscriptApril 27, 2026 | seekingalpha.comNew MarketBeat Followers Over TimeMedia Sentiment Over Time Top HeadlinesView All HeadlinesWith Nike Shares Near a 12-Year Low, Is Now the Time to Be Brave?By Sam Quirke | April 12, 2026The Real SpaceX Play: 5 Chip Stocks Powering the IPO Before It LaunchesBy Bridget Bennett | May 4, 20265 Stocks Positioned to Win the AI Data Center BuildoutBy Bridget Bennett | April 20, 2026NVIDIA's Quantum Computing Play Just Sent IonQ and Rigetti Flying By Jeffrey Neal Johnson | April 15, 20263 Biotech Stocks That Could Benefit from the Patent CliffBy Chris Markoch | April 27, 2026NTLA and CRSP Company DescriptionsCRISPR Therapeutics NASDAQ:CRSP$54.83 +2.41 (+4.60%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$54.63 -0.20 (-0.36%) As of 05/8/2026 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.CRISPR Therapeutics is a gene-editing company focused on developing transformative gene-based medicines for serious diseases using its proprietary CRISPR/Cas9 platform. CRISPR/Cas9 is a revolutionary gene-editing technology that allows for precise, directed changes to genomic DNA. CRISPR Therapeutics has established a portfolio of therapeutic programs across a broad range of disease areas including hemoglobinopathies, oncology, regenerative medicine and rare diseases. To accelerate and expand its efforts, CRISPR Therapeutics has established strategic collaborations with companies including Bayer, Vertex Pharmaceuticals and ViaCyte, Inc. CRISPR Therapeutics AG is headquartered in Zug, Switzerland, with its wholly-owned U.S. subsidiary, CRISPR Therapeutics, Inc., and R&D operations based in Cambridge, Massachusetts, and business offices in San Francisco, California and London, United Kingdom. For more information, please visit www.crisprtx.com.Intellia Therapeutics NASDAQ:NTLA$14.09 +0.38 (+2.77%) Closing price 05/8/2026 04:00 PM EasternExtended Trading$14.17 +0.08 (+0.60%) As of 05/8/2026 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more.Intellia Therapeutics, Inc., a genome editing company, focuses on the development of curative therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; NTLA-2002 for the treatment of hereditary angioedema; and NTLA-3001 for alpha-1 antitrypsin deficiency associated lung disease. It also focusses on programs comprising hemophilia A and hemophilia B; and research of proprietary programs focused on developing engineered cell therapies to treat various cancers and autoimmune diseases. In addition, the company offers tools comprising of Clustered, Regularly Interspaced Short Palindromic Repeats/CRISPR associated 9 (CRISPR/Cas9) system. It has license and collaboration agreement with Regeneron Pharmaceuticals, Inc. to co-develop potential products for the treatment of hemophilia A and hemophilia B; AvenCell Therapeutics, Inc. to develop allogeneic universal CAR-T cell therapies, and co-develop and co-commercialize allogeneic universal CAR-T cell products for an immuno-oncology indication; SparingVision SAS to develop novel genomic medicines utilizing CRISPR/Cas9 technology for the treatment of ocular diseases; Kyverna Therapeutics, Inc. for the development of an allogeneic CD19 CAR-T cell therapy for the treatment of a variety of B cell-mediated autoimmune diseases; and ONK Therapeutics, Ltd. for the development of engineered NK cell therapies to cure patients with cancer. Intellia Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSilverSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/04 - 05/08 Quantum Earnings Season Is Ramping Up—What to Watch From 2 Major Players SoundHound’s Bottom Is In—Inflection and 50% Upside Ahead? Rocket Lab Posts Record Q1 Revenue, Raises Q2 Guidance 3 Under-The-Radar Small Caps Making New All-Time Highs Flutter Sees Post-Earnings Boost as FanDuel Shows Signs of Recovery Hims & Hers Earnings Preview: The Novo Nordisk Shift Puts GLP-1 Strategy in Focus AppLovin Pops After Earnings With Growth Catalysts in Sight Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
